Investigating incretin-based therapies as a novel treatment for depression in type 2 diabetes: Findings from the South London Diabetes (SOUL-D) Study

Primary Care Diabetes

Volumn 10, Issue 2, 2016, Pages 156-159

  Moulton, C D ^a   Pickup, J C ^a   Amiel, S A ^a   Winkley, K ^a   Ismail, K ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Depressive symptoms; Incretin based therapies; Inflammation; Type 2 diabetes

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; C REACTIVE PROTEIN; EXENDIN 4; HEMOGLOBIN A1C; INCRETIN; INSULIN; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN; AUTACOID; BIOLOGICAL MARKER;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; AFFECT; AGED; BLOOD; CASE CONTROL STUDY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; ENGLAND; METABOLISM; PSYCHOLOGY; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AFFECT; AGED; ANTIDEPRESSIVE AGENTS; BIOMARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; DEPRESSION; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INFLAMMATION MEDIATORS; LONDON; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84959195239     PISSN: 17519918     EISSN: 18780210     Source Type: Journal    
DOI: 10.1016/j.pcd.2015.06.003     Document Type: Article

References (17)

1. B. Mezuk, W. Eaton, S. Albrecht, and S. Golden Depression and type 2 diabetes over the lifespan: a meta-analysis Diabetes Care 31 2008 2383 2390
2. W. Katon, C. Rutter, G. Simon, and et al. The association of comorbid depression with mortality in patients with type 2 diabetes Diabetes Care 28 11 2005 2668 2672
3. M. de Groot, R. Anderson, K. Freedland, and et al. Association of depression and diabetes complications: a meta-analysis Psychosom. Med. 63 2001 619 630
4. W. Katon, M. Von Korff, E. Lin, and et al. The Pathways Study: a randomized trial of collaborative care in patients with diabetes and depression Arch. Gen. Psychiatry 61 10 2004 1042 1049
5. J. Laake, D. Stahl, S. Amiel, and et al. The association between depressive symptoms and systemic inflammation in people with type 2 diabetes: findings from the South London Diabetes Study Diabetes Care 37 2014 2186 2192
6. J. Lovshin, and D. Drucker Incretin-based therapies for type 2 diabetes mellitus Nat. Rev. Endocrinol. 5 5 2009 262 269
7. A. Makdissi, H. Ghanim, M. Vora, and et al. Sitagliptin exerts an anti-inflammatory action J. Clin. Endocrinol. Metab. 97 9 2012 3333 3341
8. J. Matsubara, S. Sugiyama, E. Akiyama, and et al. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes Circ. J. 77 5 2013 1337 1344
9. B. Bode, M. Testa, M. Magwire, and et al. Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes Diabetes Obes. Metab. 12 7 2010 604 612
10. World Health Organisation Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications, Report of a WHO Consultation 1999 World Health Organization Geneva
11. K. Winkley, S. Thomas, S. Sivaprasad, and et al. The clinical characteristics at diagnosis of type 2 diabetes in a multi-ethnic population: the South London Diabetes cohort (SOUL-D) Diabetologia 56 6 2013 1272 1281
12. K. Twist, D. Stahl, S. Amiel, and et al. Comparison of depressive symptoms in type 2 diabetes using a two-stage survey design Psychosom. Med. 75 8 2013 791 797
13. D. McMillan, S. Gilbody, and D. Richards Defining successful treatment outcome in depression using the PHQ-9: a comparison of methods J. Affect. Disord. 127 1-3 2010 122 129
14. British National Formulary, September 2014-March 68th ed. 2015 Joint Formulary Committee
15. Y. Dai, J. Mehta, and M. Chen Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation Cardiovasc. Drugs Ther. 27 5 2013 371 380
16. A. Tremblay, B. Lamarche, C. Deacon, and et al. Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes Metabolism 63 9 2013 1141 1148
17. Y. Hu, H. Liu, R. Simpson, and A. Dear GLP-1-dependent and independent effects and molecular mechanisms of a dipeptidyl peptidase 4 inhibitor in vascular endothelial cells Mol. Biol. Rep. 40 3 2013 2273 2279